Can Digital Instruments Like the Macula-App Support AMD Therapy?

Abstract

Background A long lasting and continuous anti VEGF-therapy represents a gold standard in nAMD treatment to maintain and stabilize vision in the individual patient. Disease Management represents a daily life challenge for patients and relatives and “Real-life” clinical outcomes of patients treated with IVOM therapy are often inferior to results from randomized clinical trials. After their diagnosis, AMD-patients undergo individualized long-term therapeutic approaches. An important success factor is, that this care is patient centered and provided continuously. This study aimed at evaluating, whether digital tools, such as Makula-App 1.0 developed by the AMD-Netz can support AMD patients.

Patients and Methods The results of a user survey integrated in the Makula-App 1.0 (n = 110) as well as the results of an additional survey on the topic of “Digital appointment management in IVOM therapy” by ophthalmologists (n = 54) and patients (n = 60) were analysed with respect to use and acceptance of the Makula-App.

Results The survey revealed: 79% of Makula-App user rely on the information presented, 71% perceive the device helpful for their daily life and 80% would recommend the device. 52% of ophthalmologists and 65% of patients regard clear benefits of future digital tools for patient adherence. A digital appointment management function is rated as important by 82% of ophthalmologists.

Conclusions User perceived Makula-App 1.0 as well as its future development options as beneficial especially for the management of appointment arrangements but also as information tool. Ophthalmologists confirm the importance and usefulness of devices such as Makula-App 1.0 with respect to an optimized management of appointments and an improved patient adherence. These promising results support the future development of a Makula-App 2.0 platform, providing interfaces for an information exchange between patient and treating ophthalmologist.

Key words

AMD - macular-app - anti-VEGF-treatment - adherence - digitalization

Publication History

Received: 29 July 2021

Accepted: 06 November 2021

Article published online:
04 March 2022

• References/Literatur

• 1 Mauschitz MM, Li JQ, Larsen PP. et al. Epidemiology of severe visual impairment and blindness of old people in Germany. Ophthalmologe 2019; 116: 201-212
• 2 Stahl A. The diagnosis and treatment of age-related macular degeneration. Dtsch Arztebl Int 2020; 117: 513-520
• 3 Heimes B, Gunnemann F, Ziegler M. et al. [Compliance of age related macular degeneration patients undergoing anti-VEGF therapy: Analysis and suggestions for improvement]. Ophthalmologe 2016; 113: 925-932
• 4 Agarwal A, Aggarwal K, Gupta V. Management of neovascular age-related macular degeneration: A review on landmark randomized controlled trials. Middle East Afr J Ophthalmol 2016; 23: 27-37
• 5 Ehlken C, Helms M, Böhringer D. et al. Association of treatment adherence with real-life VA outcomes in AMD, DME, and BRVO patients. Clin Ophthalmol 2017; 12: 13-20
• 6 Finger RP, Wiedemann P, Blumhagen F. et al. Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study – A noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany. Acta Ophthalmol 2013; 91: 540-546
• 7 Heimes B, Schick T, Brinkmann CK. et al. Design of the ORCA-module in the OCEAN-study: Evaluation of SD-OCT results in daily routine practice. Ophthalmologe 2016; 113: 570-580
• 8 Holz F, Tadayoni R, Beatty S. et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol 2015; 99: 220-226
• 9 Müller S, Ehlken C, Bauer-Steinhusen U. et al. Treatment of age-related neovascular macular degeneration: the patientʼs perspective. Graefes Arch Clin Exp Ophthalmol 2017; 255: 2237-2246
• 10 Wolf A, Kampik A. Efficacy of treatment with ranibizumab in patients with wet age-related macular degeneration in routine clinical care: data from the COMPASS health services research. Graefes Arch Clin Exp Ophthalmol 2014; 252: 647-655
• 11 Ziemssen F, Bertelmann T, Hufenbach U. et al. Delayed treatment initiation of more than 2 weeks – Relevance for possible gain of visual acuity after anti-VEGF therapy under real life conditions (interim analysis of the prospective OCEAN study). Ophthalmologe 2016; 113: 143-151
• 12 Tripp A, Wauligmann A, Bouws J. et al. New Makula-App to approve adherence in IVOM-therapy. Abstractband DOG 2019. Ophthalmologe 2019; 116 (Suppl. 02) 182
• 13 Tripp A, Stasch-Bouws J, Mussinghoff P. et al. AMD: Makula-App supports patient centricity. Abstractband DOG 2020. Ophthalmologe 2020; 117: 175
• 14 Wintergerst MWM, Bouws J, Loss J. et al. Reasons for delayed and discontinued therapy in age-related macular degeneration. Ophthalmologe 2018; 115: 1035-1041